Partner With VistaraBio

Mechanistic precision for therapeutic pipelines. Novel Assays. Screening platforms. Validation. Degrader safety.

Partnership Models

Mechanistic discovery, degrader co-development, small-molecule programs, peptide therapeutics, and assay access.

What Partners Gain

Mechanistic derisking, accelerated discovery, precision design, and translational biomarkers.

---

Choose from our Pipeline

Pipeline Overview

Mechanism-driven programs across degraders, small molecules, peptides, and assays.

Degrader Programs

CRBN glue discovery, Parkin glue exploration, context-specific glue mapping.

Small Molecule Programs

BRD4 kinase inhibitors, SUMO-switch modulators, JAK-STAT regulators.

Peptide Therapeutic Programs

Parkin cohort restoration, PD PTM-corrective peptides, proteostasis signature modulators.

Assay Platform Programs

TSA-CRBN, BRD4 kinase screening, MG-OS, PD PTM assays.

Mechanistic Stage-Gating

Substrate logic → PTM architecture → cohort assembly → glue/catalytic consequence → biomarkers.

---